NO-MODIFIED SAQUINAVIR IS EQUALLY EFFICIENT AGAINST DOXORUBICIN SENSITIVE AND RESISTANT NON-SMALL CELL LUNG CARCINOMA CELLS

Sanja Mijatović1, Milica Pešić2, Marija Mojić1, Jasna Banković2, Đorđe Miljković1, Paolo Fagone3, Katia Mangano3, Ferdinando Nicoletti3, James McCubrey4, Nikola Tanić2, Danijela Maksimović-Ivanić1

1Department of Immunology, Institute for Biological Research »Siniša Stanković«, University of Belgrade, Belgrade, Serbia
2Department of Neurobiology, Institute for Biological Research »Siniša Stanković«, University of Belgrade, Belgrade, Serbia
3Department of Bio-Medical Sciences, University of Catania, Catania, Italy
4Department of Microbiology and Immunology, Brody School of Medicine at East Carolina University, Greenville, North Carolina

Summary

Background: The NO-modified form of the HIV inhibitor saquinavir (Saq-NO) inhibited the growth of a variety of cancer cell lines in vitro and in vivo more potently than the original compound in a nontoxic fashion. In addition, chemosensitizing properties were observed. The aim of the present study was to evaluate its anticancer action against non-small cell lung carcinoma cells in their doxorubicin (DOXO) sensitive and resistant phenotype (NCI-H460 and NCI-H460/R).

Methods: The viability of cells was analyzed by MTT and crystal violet assays. DR5 expression was estimated by real time RT-PCR and flow cytometry. Activity of P-glycoprotein (P-gp) pumps was evaluated by the Rho123 accumulation assay.

Results: Saq-NO diminished the viability of lung cancer cells through induction of cell cycle arrest in the G0/G1 phase independently of the overexpression of the P-gp pumps. In addition, Saq-NO elevated or completely reconstituted the doxorubicin efficacy in NCI-H460 and NCI-H460/R, respectively. The chemosensitizing effect in DOXO resistant cells was a consequence of P-gp inhibition which was found to be...
more potent than that observed with dex-verapamil, a conventional inhibitor of P-gp. Sensitization to DOXO upon Saq-NO was accompanied by elevated DR5 expression, but the resistance to TRAIL was not abrogated.

**Conclusions:** The NO-modified HIV inhibitor saquinavir displayed equal antiproliferative and chemosensitizing properties in DOXO sensitive and resistant non-small cell lung carcinoma cells, suggesting the importance of the evaluation of this drug as an antineoplastic agent.

**Keywords:** chemosensitization, non-small cell lung carcinoma cells, saquinavir, saquinavir-NO, tumor toxicity (14–20). The unique mechanism of its tumoricidal action includes nonaggressive inhibition of proliferation due to suppression of S6 protein which is important in the translation of 5’ terminal oligopyrimidine (TOP) containing mRNA and induction of differentiation towards the normal nonmalignant phenotype (18). Apart from these important features, Saq-NO was able to sensitize the tumor cells to chemosensitive or nonselectively affected both NSLC phenotypes either susceptible or not to the conventionally used chemotherapeutic drug doxorubicin. Besides its direct antiproliferative potential, Saq-NO was effective against both doxorubicin sensitive and resistant NSCLC cell lines. Finally, Saq-NO amplified the expression of TRAIL specific death receptor without restoration of its functionality.

**Material and Methods**

**Reagents and cells**

Fetal calf serum (FCS), RPMI-1640, phosphate-buffered saline (PBS), dimethyl sulfoxide (DMSO), and propidium iodide (PI) were obtained from Sigma (St. Louis, MO). The NCI-H460 human non-small lung carcinoma cell line was purchased from the American Type Culture Collection (ATCC) (Manassas, VI). Cells were routinely maintained in HEPES-buffered RPMI-1640 medium supplemented with 10% FCS, 2 mmol/L L-glutamine, 0.01% sodium pyruvate, and antibiotics (culture medium) at 37 °C in a humidified atmosphere with 5% CO2. After trypsinization, cells were seeded at 4 × 105/well in 96-well plates for viability determination and 1.5 × 104/well for flow cytometry and RNA extraction.

**Introduction**

Lung cancer is a complex malignant disease with a variety of histological types. Non-small cell lung carcinoma (NSCLC) is one of the most frequent types of lung cancer and it accounts for approximately 75% of all lung carcinomas. Currently, chemotherapy remains the mainstay of treatment; unfortunately, the 5-year survival of patients is still poor, fixed at 15%, without significant improvement over the last two decades (1).

Loss of sensitivity to death receptor-mediated killing by immune system products, as well as the rapid development of the chemoresistant phenotype, are recognized as the leading causes of the low rate of curability of NSCLC. Both phenomena are frequently connected to the establishment of intracellular resistance to induction of apoptosis (2). Therefore, new drugs with the ability to overcome this barrier and remove the death pathway blockage are extremely desirable. Saquinavir-NO (Saq-NO) represents a modality of the HIV protease inhibitor saquinavir. Saquinavir (Saq) was created to inhibit the formation of infective viral particles through blockage of the HIV enzyme active site (3). However, it was found that this drug effectively suppressed the development of HIV-related malignancies or reduced their presence (4). This property was subsequently investigated, and it was shown that inhibition of the PI3K-Akt signaling pathway and proteosome activity were connected with its antitumor feature (4–12). Unfortunately, the presence of side effects seriously limited Saq usage and presented the opportunity for designing different forms of this drug with an advanced pharmacological profile (13). Attachment of the nitric oxide (NO) moiety to saquinavir generated a new drug with significantly improved antitumor characteristics (14). Saq-NO was completely nontoxic in vitro and in vivo, while its activity against a wide range of cell lines was qualitatively and quantitatively increased in comparison to the parental drug (14). The novel agent was efficient in numerous syngeneic and xenograft tumor models without exhibiting any signs of biochemical or visible
10^5/well in 6-well plates for flow cytometric analysis. Resistant NCI-H460/R cells were selected originally from NCI-H460 cells by exposure to gradually increasing concentrations of doxorubicin (21).

**Determination of cell viability by MTT and crystal violet assay**

For the determination of cell viability, the crystal violet (CV) and mitochondrial dehydrogenase tests (MTT) were performed. Cells (4 x 10^2/well) were cultivated in the presence of a wide range of drug doses for 48 h and viability was determined as previously described (22). The results are presented as percentage of the control (untreated cells), that was arbitrarily set to 100%.

**Cell cycle analysis**

Cells were treated with 18.8 μmol/L of Saq and Saq-NO, trypsinized and fixed in 70% ethanol at 4 °C overnight. Cells were stained with a solution containing PI (20 μg/mL) and RNase (0.1 mg/mL) for 30 min at 37 °C in the dark. After each step, cells were washed with PBS, and red fluorescence was analyzed on a FACS Calibur flow cytometer (BD, Heidelberg, Germany). The distribution of cells in different cell cycle phases was determined with Cell Quest Pro software (BD) (23).

**Isobologram analysis**

Isobologram analysis was used to determine the type of interaction between Saq-NO and recombinant human TRAIL. Isobolograms were created after treatment with a wide range of Saq-NO concentrations (4.7–18.8 μmol/L) with different concentrations of TRAIL (6.2–50 ng/mL). Combinations reaching 30–70% of cytotoxicity were expressed as concentrations of single agent alone leading to the observed amount of toxicity. Analysis was done using dose-response curves after exposure to Saq-NO alone, TRAIL alone, or their combination for 24 h (15, 24).

**RNA isolation and relative quantification of DR5 mRNA by real time RT-PCR**

Total RNA was isolated from NCI-H460 and NCI-H460/R cells using TRIZOL reagent (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. Two μg of RNA were converted to cDNA by reverse transcription (RT) reactions in a 100 μL volume with random hexamer primers using High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, USA) following the manufacturer’s instructions. The reactions were performed under RNase-free conditions at 25 °C for 10 min and 37 °C for 2 h. Each RT reaction was accompanied by a no-RT control in which the reverse transcriptase was replaced by DEPC treated water.

The expression of DR5 mRNA was evaluated by SYBR Green (Applied Biosystems) real time RT-PCR. PCR was performed using ABI Prism 7000 Sequence Detection System (Applied Biosystems) in a total volume of 25 μL containing 1x SYBRGreen PCR master mix with AmpErase UNG (Applied Biosystems), 0.5 μmol/L primers and cDNA template (20 ng of RNA converted to cDNA) at cycle conditions: 2 min at 50 °C for dUTP activation, 10 min at 95 °C for initial denaturation and Taq polymerase activation, followed by 40 cycles at 95 °C for 15 s and 60 °C for 60 s. Primer pairs (Sigma) were: for DR5 5'-TGC AGC GCT AGT CTT CGT GAT TG-3' and 5'-GCC AGT CTGCAAAGTCA-3' and for GAPDH 5'-CACGGCATGATCGGCATGCTG-3' and 5'-CATCCATGACAATTTGG TAT CG-3' and 5'-CCA TCA CGC CAC AGT TTC C-3'. The experimental threshold was calculated from the mean baseline fluorescence signal from cycle 3 to 15, plus 10 standard deviations. The point at which the amplification plot crosses this threshold is defined as Ct. No template control was used in each run. Each sample was run in triplicate and a mean value of each Ct triplicate was used for further calculation. A reference, endogenous control, was included in every analysis to correct the differences in inter-assay amplification efficiency, and the expression of each gene was normalized to GAPDH (glyceraldehyde-3-phosphate dehydrogenase) expression. Quantification was performed by the 2-ΔΔCt method (25). The results obtained were analyzed by RQ Study Add ON software for 7000 v 1.1 SDS instrument (ABI Prism Sequence Detection System) with a confidence level of 95% (p<0.05).

**DR5 membrane expression**

The expression of DR5 was assessed by flow cytometry as previously described (24). After the 24 h of treatment with 18.8 μmol/L, Saq-NO cells were detached with PBS-EDTA (1 mmol/L), incubated in PBS–10% FCS for 1 h for membrane reconstitution, and then stained with anti-DR5 antibody (mouse anti-human DR5, Biosource International, Camarillo, CA) 45 min at RT. After washing in PBS–0.5% BSA, cells were incubated for 30 min at RT with secondary TRIC-conjugated goat anti-mouse IgG (ZymedTM, Invitrogen) washed twice with PBS–0.5% BSA and finally resuspended in PBS. Analysis was performed on a FACS Calibur flow cytometer using CellQuest software.

**Rho123 accumulation assay**

Rho123 accumulation was analyzed by flow cytometry utilizing the ability of Rho123 to emit fluorescence. The intensity of the fluorescence was proportional to Rho123 accumulation. Studies were per-
formed with dex-VER and Saq-NO. NCI-H460/R cells were grown to 80% confluence in 75 cm² flasks, trypsinized and resuspended in 10 mL centrifuge tubes in a Rho123-containing medium. Then, the cells were treated with Saq-NO and VER (18.8 μmol/L) and incubated at 37 °C in 5% CO₂ for 30 min. At the end of the incubation period, the cells were pelleted by centrifugation, washed with PBS and placed in cold PBS. The samples were kept on ice in the dark until analysis on a FACS caliber flow cytometer (Becton Dickinson, Oxford, United Kingdom). The fluorescence of Rho123 was assessed on fluorescence channel 2 (FL2-H) at 530 nm. A minimum of 10,000 events were assayed for each sample. The differences in curve shape were quantified using a Kolmogorov–Smirnov nonparametric statistic. P values were calculated (available on request) in CellQuest Pro and run on a Macintosh computer.

**Statistical analysis**

The results are presented as mean ± SD of triplicate observations from the representative of three experiments, except if indicated otherwise. The significance of the difference between treatments and control was analyzed by ANOVA followed by Student–Newman–Keuls test. P<0.05 was considered significant.

**Results**

**Saq-NO decreased the viability of both doxorubicin sensitive and resistant NSCLC cells**

To investigate the effects of Saq-NO and Saq on the viability of sensitive NSCLC cells (NCI-H460) and compare it with their potential to inhibit the growth of doxorubicin resistant NSCLC cells (NCI-H460/R), cells were exposed to a wide range of doses for 48 h when the number of viable cells was measured by both MTT and CV assays. As can be seen in Figure 1, Saq-NO decreased the mitochondrial respiration (left panel) and the viability (right panel) of NCI-H460 cells more potently than its parental drug, Saq. Importantly, the same pattern of action of the HIV protease inhibitor and its NO-modified form was observed in the doxorubicin resistant form of this cell line. The results obtained from the viability assays clearly indicated that NO-modified Saquinavir possesses stronger potential to suppress the growth of doxorubicin sensitive and resistant non-small lung carcinoma cells than the original drug (Figure 1A). It was previously observed that Saq-NO acted basically through decreasing their dividing potentials. To determine the reason for the abrogated viability observed in NCI-H460 or NCI-H460/R cells after exposure to Saq-NO, cell cycle distribution was estimated. For that purpose, NCI-H460 and NCI-H460/R cells were incubated for 48 h with doses at the IC₅₀ level. Flow cytometric analysis revealed a remarkable G₀/G₁ arrest in cultures exposed to the drug independently from their sensitivity to doxorubicin. In parallel with this, an insignificant amount of hypodiploid cells was detected upon the treatment indicating that inhibition of proliferation rather than apoptosis was responsible for the diminished number of cells observed after the treatment with Saq-NO. Ann/PI double staining confirmed the absence of both early and late apoptotic cells in NCI-H460 and NCI-H460/R cells (data not shown) confirming the nonaggressive suppression of tumor cell growth. In summary, overexpression of P-gp in NSCLC cells did not alter the capacity of Saq-NO to downregulate the rate of cell division and decrease their malignant potential.

**Saq-NO increased the sensitivity of NSCLC cells to doxorubicin**

Since we observed that Saq-NO was equally efficient against doxorubicin sensitive and resistant cells, it was of interest to evaluate its capacity to provoke or to revert the sensitivity to the chemotherapeutic drug. NCI-H460 and NCI-H460/R cells were treated with Saq-NO for 4 h prior to doxorubicin application. Cell viability was measured by the CV test after the 48 h. As shown in Figure 2A, Saq-NO amplified the toxicity of doxorubicin in both sensitive and resistant cells under these experimental conditions. These effects were observed when the cells were exposed to both treatments simultaneously. The viability of cells simultaneously treated with Saq-NO and doxorubicin was significantly lower in comparison to their viability when treated with doxorubicin alone and the effect was more obvious on NCI-H460/R cells, as expected (Figure 2B). Importantly, the chemosensitizing capacity of Saq-NO was more potent than the one observed with the P-gp inhibitor dex-verapamil, or original drugs in the same doses (4.5 left or 9 μmol/L, right) (Figure 2C). Taken together, Saq-NO is able to sensitize the resistant cells to one of the most frequently used chemotherapeutic drugs, doxorubicin, and to decrease the efficient dose in sensitive clones.

**Saq-NO blocked the P-gp pumps**

The ability of Saq-NO to sensitize the resistant NCI-H460/R cells to doxorubicin indicated the possibility that the target for its action are P-gp pumps which are overexpressed in these cells. To evaluate this hypothesis, the cells were exposed to 18.8 μmol/L of either Saq-NO or dex-verapamil for 30 min and then the capacity of the cells to export the Rho123 stain was measured by flow cytometric analysis (Figure 3). Cells exposed to Saq-NO exhibited increased Rho123 fluorescence, confirming that Saq-NO blocked the P-gp pumps more potently than the commercial P-gp inhibitor dex-verapamil.
Figure 1 Saq-NO decreased viability of both DOXO-sensitive and DOXO-resistant human NSCLC cell lines. A, NCI-H460 and NCI-H460/R cells (4 × 10³ cells/well) were treated with a range of concentrations of Saq or Saq-NO for 48 h after which cell viability was estimated by MTT (left panel) and CV (right panel) tests. The data are presented as the mean ± S.D. from a representative of three independent experiments. *, p < 0.05, refers to untreated cultures. B, Cells were treated with IC50 dose (18.8 μM) of Saq-NO or left untreated (control) and cell cycle analysis was performed by flow cytometry after 48 h.
Figure 2 Saq-NO is more potent than dex-verapamil in sensitizing human NSCLC cells to DOXO. NCI-H460 and NCI-H460/R cells (4 × 10^3 cells/well) were pretreated with various doses of Saq-NO for 6 h (A) or simultaneously treated with a range of DOXO concentrations (B). After 48 h of DOXO treatment, cell viability was estimated by CV. C, NCI-H460/R cells (4 × 10^3 cells/well) were simultaneously treated with 4.7 μmol/L (left panel) or 9.4 μmol/L (right panel) of dex-ver, Saq or Saq-NO and with a range of concentrations of DOXO and after 48 h cell viability was evaluated by CV. The data are presented as the mean ± S.D. from a representative of three independent experiments. *, p < 0.05, refers to untreated cultures.
Figure 3 Saq-NO inhibited P-gp activity. NCI-H460/R cells were treated with Saq, Saq-NO or dex-ver (18.8 µmol/L) or left untreated (control) for 30 min and Rho123 accumulation was analyzed by flow cytometry.

Figure 4 SSaq-NO upregulated DR5 expression at mRNA and membrane level. NCI-H460 (A) and NCI-H460/R (B) cells were treated with Ver or Saq-NO (18.8 µmol/L for 24 h and qRT PCR analyses for DR5 mRNA was performed (upper panels) or cells were treated with Saq, Saq-NO, dex-Ver or TQ (18.8 µmol/L) for 24 h after which DR5 membrane expression was analyzed by flow cytometry (lower panels).
Saq-NO increased the expression of death receptor 5 (DR5)

One of the main characteristics of NSCLC, which is often associated with the resistance to apoptosis induced by chemotherapy, is its loss of membrane death receptors able to bind the TRAIL molecule, one of the most potent products of the immune system in elimination of cancer cells (26, 27). To evaluate the possible influence of Saq-NO on DR5 gene expression, cells were exposed to 18.8 \( \mu \text{mol/L} \) of either Saq-NO or dex-verapamil and the expression of DR5 was examined by real-time RT-PCR. Both drugs elevated DR5 mRNA expression in sensitive NCI-H460 cells, while in NCI-H460/R cells significant gene expression of this receptor was observed under the Saq-NO but not dex-verapamil treatment (Figure 4 upper panel). DR5 expression correlated with its presence on the membrane of cells (Figure 4 lower panel). While the competitive inhibitor, dex-verapamil, and the noncompetitive inhibitor, tariquidar (TQ), did not alter the presence of DR5 on the membrane of either NCI-H460 or NCI-H460/R cells, the expression of this receptor was elevated after the exposure to Saq-NO.

Saq-NO antagonized the TRAIL activity

The potential of Saq-NO to elevate the expression of DR5 indicated its possibility to reverse the sensitivity of these cells to selective antitumor response driven by ligation of TRAIL to this receptor. To clarify this possibility, NCI-H460 and NCI-H460/R cells resistant to TRAIL were treated in parallel with this molecule and Saq-NO (Figure 5). Cell viability was estimated by MTT tests and isobologram curves were created. Unfortunately, interaction between Saq-NO and TRAIL was antagonistic suggesting that, apart from Saq-NO potential to amplify the DR5 expression, it was not able to exclude blockage at the intracellular level which may be responsible for the ineffective response to TRAIL.

Discussion

Numerous studies performed during the last decade indicate that antiinflammatory or antimicrobial drugs could target cancer cells (28). One of the promising candidates are the HIV protease inhibitors which, due to the inhibition of PI3K/Akt signaling pathway and proteasome activity, suppress the growth of not just HIV-related malignancies but also various types of tumors (4–12). Poor pharmacological profile of these drugs as well as high toxicity seriously compromised their utilization and indicated the need for their modification (13). In order to improve its quality, we attached a NO moiety to Saq (14). Recently, we found that NO-modified Saq efficiently inhibited the progression of tumor cells derived from rodent or human origin in vitro as well as in syngeneic and xenograft models (14–19). An absence of Saq-NO toxicity was observed on primary cells in vitro and was further confirmed by studies of acute and subacute toxicity (14). The results revealed the impressive fact that the NO-modified compound was completely innoxious when it was applied in a dose corresponding to a 100% lethal dose of parental drug. A major aspect of Saq-NO action was its capacity to stop the tumor growth in a nonaggressive manner. Rodent melanoma, glioma cells and colon cancer cells underwent the process of differentiation/transdifferentiation after time-limited exposure to Saq-NO (14, 19). Loss of their malignant potential and metastatic capacities were accompanied by chemosensitization as well as reconstitution of their sensitivity to the TRAIL-mediated immune response (15, 18). Moreover, its efficacy was impressive even in multidrug (MDR) resistant forms of prostate cancers (20). NSCLC is one of the most aggressive forms of tumor which during its progression loses the sensitivity to death receptor-mediated antitumor activities and response to chemotherapy. NSCLC rapidly progresses to the apoptotic resistant form (2). Here, we have
compared the capacity of Saq-NO to downregulate the growth of two phenotypes of NSCLC, sensitive and resistant to doxorubicin. As previously observed in a panel of cell lines, Saq-NO exerted tumoricidal effects in lower concentrations than Saq which was independent from the expression of P-gp pumps (14–20). Similarly to our previous observations, Saq-NO induced cell cycle arrest in the G0/G1 phase and therefore decreased the proliferation of NSCLC. The ability to stop the growth of both types of NSCLC, sensitive and resistant, is very important to determine the role of P-gp in cancer cells that limit the application of chemotherapy. ATP-dependent pumps are responsible for the transfer of substances across biological membranes and, therefore, drugs across tissue barriers in cancer cell chemoresistant phenotypes (29–32). Saq-NO application 4 h before or simultaneously with DOXO decreased the efficient dose of this chemotherapeutic drug in sensitive cells and, more importantly, sensitized the resistant cells to this chemotherapeutic drug. Recently, it was observed that Saq can be a substrate of P-glycoprotein and also an inhibitor of the breast cancer resistance protein (BCRP1, gene product of ABCG2) (33–36). On the other hand, Rotwailer et al. demonstrated that Saq-NO sensitized P-gp–, MRP1–, or BCRP1-expressing prostate cancer cells to chemotherapy. Similarly, in NSCLC cells, Saq-NO inhibited the P-gp more effectively than the competitive inhibitor dext-verapamil (20). This is important due to the known toxicity of competitive ATP-Binding Cassette (ABC) transporter inhibitors and, therefore, the development of new less toxic drugs with the capacity to inhibit ABC transporters could be beneficial (29, 32, 37, 38). Namely, simultaneous administration of anticancer drugs and compounds that can impede the efflux of chemotherapeutic agents by ABC transporters can concomitantly modulate various cytochrome P450 (CYP450) enzymes, consequently influencing their anticancer drug metabolism. This can further result in unfavorable drug–drug interactions and altered pharmacokinetic properties of the applied anticancer drugs with additional adverse cytotoxic side effects (39). Thus, the first generation of P-gp inhibitor drugs confirmed the effect of a P-gp modulation to overcome MDR, but most of these drugs had limited clinical implementation because the administered doses were either noneffective or toxic for the patient. The second generation of P-gp inhibitors had reduced primary toxicity, however, they showed important pharmacological interactions which caused disturbed metabolism and accumulation of chemotherapeutic drugs, what finally lead to exaggerated toxicity as well. Finally, the third generation of inhibitors was designed for low pharmacokinetic interactions and high transporter affinity, but their efficacy has not yet been confirmed by clinical evidence summarized in Szakács et al. (29).

In addition to its potential to restore sensitivity to chemotherapy through drug pump inhibition, equal efficacy of Saq-NO against the sensitive and resistant type of NSCLC cells indicated that transporter proteins are not the barrier for its intrinsic capacity to effectively stop the division of non-small lung cancer cells. Moreover, strong antitumor potential observed in vitro was not accompanied by the induction of cell death. This is a very important feature of the Saq-NO mode of action, if it is well defined that induction of apoptosis is an undesirable way to treat the cancer in highly aggressive forms, such as this type of cancer. Having in mind that NSCLC rapidly adopts an apoptotic resistant phenotype in response to chemotherapy, it seems that efficacy of Saq-NO could be ascribed to its potential to inhibit the proliferation of these cells rather than kill them (2).

Development of an apoptotic resistant phenotype is often correlated with the loss of sensitivity to death signals triggered by immune cell products such as TRAIL (26, 27). This molecule is one of the most selective mediators of tumor cell death able to induce the apoptosis of transformed but not normal cell after ligation to its specific receptor. Cancer cells evade this through the lack of expression of its receptors or development of intracellular blockage in delivering the death signal triggered upon ligation. Saq-NO was able to upregulate the expression of DR5 in both DOXO sensitive and resistant cancer cells. In spite of this, TRAIL was not able to induce the apoptotic process. It is obvious that intracellular blockade responsible for apoptotic resistance was not eliminated by Saq-NO application. It was previously observed that Saq-NO efficiently restores the TRAIL-mediated antitumor response not just through upregulated expression of DR5 but also through a decrease in the expression of natural caspase-3 inhibitor XIAP in prostate cancer (18). The explanation of the unsuccessful immunosensitization by Saq-NO under these circumstances could be related to the described feature of NSCLC cells to be unable to mediate the posttranslational modifications of DRs and/or to bring to the membrane their non-functional forms (26, 27). These data are in disharmony with the previously found enhancement of TRAIL-induced apoptosis in P-gp-overexpressing leukemia and breast cancer cells, indicating that the intrinsic characteristics of cancer cells are crucial for the outcome of the treatment (40, 41). The capability of Saq-NO to function in a slow cytostatic and differentiating manner, and its potential to nonselectively target various types of tumors, even the most aggressive MDR forms, draw attention to the importance of further analysis of this class of drugs as antineoplastic agents.

Acknowledgement. This work was partly supported by the Serbian Ministry of Science, Technology and Development of the Republic of Serbia (Grants No 173013 and III41031).

Conflict of interest statement
The authors stated that there are no conflicts of interest regarding the publication of this article.
References

1. Tonon G, Wong KK, Maulik G, Brennan C, Feng B, Zhang, Y, et al. High-resolution genomic profiles of human lung cancer. PNAS 2005; 102: 9625–30.
2. Fennell DA. Caspase regulation in non-small cell lung cancer and its potential for therapeutic exploitation. Clin Cancer Res 2005; 11: 2097–105.
3. Deeks SG, Smith M, Holodniy M, Kahn JO. HIV-1 protease inhibitors. A review for clinicians. JAMA 1997; 277: 145–53.
4. Sgadari C, Barillari G, Toschi E, Carlei D, Bacigalupo I, Baccarini S, et al. HIV protease inhibitors are potent anti-angiogenic molecules and promote regression of Kaposi sarcoma. Nat Med 2002; 3: 225–32.
5. Chow WA, Guo S, Valdes-Albini F. Nelfinavir induces liposarcoma apoptosis and cell cycle arrest by up-regulating sterol regulatory element binding protein-1. Anticancer Drug 2006; 17: 891–903.
6. Pajonk F, Himmelsbach J, Riess K, Sommer A, McBride WH. The human immunodeficiency virus (HIV)-1 protease inhibitor saquinavir inhibits proteasome function and causes apoptosis and radiosensitization in non-HIV-associated human cancer cells. Cancer Res 2002; 62: 5230–5.
7. Ikezoe T, Daar ES, Hisatake J, Taguchi H, Koeffler HP. HIV-1 protease inhibitors decrease proliferation and induce differentiation of human myelocytic leukemia cells. Blood 2000; 96: 3553–9.
8. Gills JJ, Lopiccolo J, Tsurutani J, Shoemaker RH, Best CJ, Abu-Asab MS, et al. Nelfinavir, a lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. Clin Cancer Res 2007; 13: 5183–94.
9. Ikezoe T, Hisatake Y, Takeuchi T, Ohtsuki Y, Yang Y, Said JW, et al. HIV-1 protease inhibitor, ritonavir: a potent inhibitor of CYP3A4, enhanced the anticancer effects of docetaxel in androgen-independent prostate cancer cells in vitro and in vivo. Cancer Res 2004; 64: 7426–31.
10. Cuneo KC, Tu T, Geng L, Fu A, Hallahan DE, Willey CD. HIV protease inhibitors enhance the efficacy of irradiation. Cancer Res 2007; 67: 4886–93.
11. Ikezoe T, Saito T, Bandobashi K, Yang Y, Koeffler HP, Taguchi H. HIV-1 protease inhibitor induces growth arrest and apoptosis of human multiple myeloma cells via inactivation of signal transducer and activator of transcription 3 and extracellular signal-regulated kinase 1/2. Mol Cancer Ther 2004; 3: 473–9.
12. Gupta AK, Cerniglia GJ, Mick R, McKenna WG, Muschel RJ. HIV protease inhibitors block Akt signaling and radiosensitize tumor cells both in vitro and in vivo. Cancer Res 2005; 65: 8256–65.
13. Flexner C. HIV-protease inhibitors. Drug Ther 2006; 358: 1281–92.
14. Maksimovic-Ivanić D, Mijatović S, Miljković D, Harhaji-Trajković L, Timotijević G, Mojić M, et al. The antitumor properties of a nontoxic, nitric oxide-modified version of saquinavir are independent of Akt. Mol Cancer Ther 2009; 8: 1169–78.
15. Mijatović S, Maksimovic-Ivanić D, Mojić M, Timotijević G, Miljković D, Mangano K, et al. Cytotoxic and immune-sensitizing properties of nitric oxide-modified Saquinavir in iNOS-positive human melanoma cells. J Cell Physiol 2011; 226: 1803–12.
16. Donia M, Maksimovic-Ivanić D, Mijatović S, Mojić M, Miljković D, Timotijević G, et al. In vitro and in vivo anticancer action of Saquinavir-NO, a novel nitric oxide-derivative of the protease inhibitor saquinavir, on hormone resistant prostate cancer cells. Cell Cycle 2011; 10: 492–9.
17. Donia M, Mangano K, Fagone P, De Pasquale R, Dinotta F, Coco M, et al. Unique antineoplastic profile of Saquinavir-NO, a novel NO-derivative of the protease inhibitor Saquinavir, on the in vitro and in vivo tumor formation of A375 human melanoma cells. Oncol Rep 2012; 28: 682–8.
18. Mojić M, Mijatović S, Maksimovic-Ivanić D, Dinić S, Grdović N, Miljković D, et al. Saquinavir-NO-targeted 56 protein mediates sensitivity of androgen-dependent prostate cancer cells to TRAIL. Cell Cycle 2012; 11: 1174–82.
19. Mojić M, Mijatović S, Maksimovic-Ivanić D, Miljković D, Stošić-Grujičić S, Stanković M, et al. Therapeutic potential of nitric oxide-modified drugs in colon cancer cells. Mol Pharmacol 2012; 82: 700–10.
20. Rothweiler F, Michaelis M, Brauer P, Otte J, Weber K, Fehse B, et al. Anticancer effects of the nitric oxide-modified saquinavir derivative saquinavir-NO against multidrug-resistant cancer cells. Neoplasia 2010; 12: 1023–30.
21. Pešić M, Marković JZ, Janković D, Kanazir S, Marković ID, Raklić L, et al. Induced resistance in the human non small cell lung carcinoma (NCI-H460) cell line in vitro by anticancer drugs. J Chemother 2006; 18: 66–73.
22. Mijatović S, Maksimovic-Ivanić D, Radović J, Miljković Dj, Harhaji Lj, Vučković O, et al. Anti-glioma action of aloe emodin: the role of ERK inhibition. Cell Mol Life Sci 2005; 62: 589–98.
23. Kaluderović GN, Mijatović SA, Zmejkovski BB, Bulatović MZ, Gómez-Ruiz S, Mojić MK, et al. Platinum(II/IV) complexes containing ethylenediamine-N,N'-di-2/3-propionate ester ligands induced caspase-dependent apoptosis in cisplatin-resistant colon cancer cells. Metallomics 2012; 4: 979–87.
24. Huerta-Yépez S, Vega M, Escoto-Chavez SE, Murdock B, Sakai T, Baritaki S, Bonavida B. Nitric oxide sensitizes tumor cells to TRAIL-induced apoptosis via inhibition of the DR5 transcription repressor Yin Yang 1. Nitric Oxide 2009; 20: 39–52.
25. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using Real-Time quantitative PCR and the 2-ΔΔCt method. Methods 2001; 25: 402–8.
28. Rigas B, Williams JL. NO-donating NSAIDs and cancer: an overview with a note on whether NO is required for their action. Nitric Oxide. 2008; 19: 199–204.
29. Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 2006; 5: 219–34.
30. Szakács G, Váradi A, Ozvegy-Laczka C, Sarkadi B. The role of ABC transporters in drug absorption, distribution, metabolism, excretion and toxicity (ADME-Tox). Drug Discov Today 2008; 13: 579–93.
31. Zhou SF, Wang LL, Di YM, Xue CC, Duan W, Li CG, Li Y. Substrates and inhibitors of human multidrug resistance associated proteins and the implications in drug development. Curr Med Chem 2008; 15: 1981–2039.
32. Gatti L, Beretta GL, Cossa G, Zunino F, Perego P. ABC transporters as potential targets for modulation of drug resistance. Mini Rev Med Chem 2009; 9: 1102–12.
33. Williams GC, Liu A, Knipp G, Sinko PJ. Direct evidence that saquinavir is transported by multidrug resistance–associated protein (MRP1) and canalicular multispecific organic anion transporter (MRP2). Antimicrob Agents Chemother 2002; 46: 5456–62.
34. Gupta A, Zhang Y, Unadkat JD, Mao Q (2004). HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP1/ABCG2). J Pharmacol Exp Ther 2004; 310: 334–41.
35. Dallas S, Ronaldson PT, Bendayan M, Bendayan R. Multidrug resistance protein 1–mediated transport of saquinavir by microglia. Neuroreport 2004; 15: 1183–6.
36. Ronaldson PT, Lee G, Dallas S, and Bendayan R. Involvement of P-glycoprotein in the transport of saquinavir and indinavir in rat brain microvessel endothelial and microglia cell lines. Pharm Res 2004; 21: 811–8.
37. Lage H. An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol Life Sci 2008; 65: 3145–67.
38. Fletcher JI, Haber M, Henderson MJ, Norris MD. ABC transporters in cancer: more than just drug efflux pumps. Nat Rev Cancer 2010; 10: 147–56.
39. Darby R, Callaghan R, McMahon RM. P-glycoprotein Inhibition: The Past, the Present and the Future. Current Drug Metabolism 2011; 12: 722–31.
40. Park SJ, Wu CH, Choi MR, Najafi F, Emami A, Safa AR. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5. Biochem Pharmacol 2006; 72: 293–307.
41. Park SJ, Bijangi-Vishhehsraaei K, Safa AR. Selective TRAIL-triggered apoptosis due to overexpression of TRAIL death receptor 5 (DR5) in P-glycoprotein-bearing multidrug resistant CEM/VBL1000 human leukemia cells. Int J Biochem Mol Biol 2010; 1: 90–100.

Received: August 6, 2013
Accepted: September 6, 2013